<HashMap><database>biostudies-arrayexpress</database><scores/><additional><submitter>Kevin Schmidt</submitter><organism>Homo sapiens</organism><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/E-MTAB-16034</full_dataset_link><description>This study aimed to explore the therapeutic potential of the cysteine protease inhibitor aloxistatin (E64d) as a candidate to combat cardaic fibrotic progression. Human cardiac fibroblasts (HCFs) derived from diseased myocardium including ischemic and dilated cardiomyopathies (ICM, DCM) were treated for 48 h with 100 µM aloxistatin or DMSO control and pro-fibrotic stimulated with 5 ng/mL TGFβ1 or respective vehicle (veh) control (4 mM HCl containing 0.1% bovine serum albumin). HCF were harvested with QiAzol Lysis reagent (Qiagen) and RNA was isolated based on phenol-chloroform-extraction procedure.</description><repository>biostudies-arrayexpress</repository><sample_protocol>Nucleic Acid Extraction - RNA was isolated based on phenol-chloroform-extraction procedure.</sample_protocol><sample_protocol>Library Construction - polyA enrichment library preparation was performed by Novogene</sample_protocol><sample_protocol>Sample Collection - HCF were harvested with QiAzol Lysis reagent (Qiagen)</sample_protocol><sample_protocol>Sequencing - Illumina (NovaSeq X Plus) platform was used for paired end 150 bp sequencing (30 M reads per sample). Sequencing was done by Novogene.</sample_protocol><figure_sub>Organization</figure_sub><figure_sub>MINSEQE Score</figure_sub><figure_sub>Assays and Data</figure_sub><figure_sub>Processed Data</figure_sub><figure_sub>MAGE-TAB Files</figure_sub><data_protocol>Data Transformation - DESeq2 pipeline (for R) was used for count normalization and DEG calculation with default parameters</data_protocol><data_protocol>Sequence Alignment - mapping to GRCh38 with STAR aligner using default parameters</data_protocol><omics_type>Metabolomics</omics_type><omics_type>Unknown</omics_type><omics_type>Transcriptomics</omics_type><omics_type>Genomics</omics_type><omics_type>Proteomics</omics_type><instrument_platform>Illumina NovaSeq X</instrument_platform><study_type>RNA-seq of coding RNA</study_type><species>Homo sapiens</species><pubmed_authors>Maria Jordan</pubmed_authors><pubmed_authors>Kevin Schmidt</pubmed_authors><pubmed_authors>jan Fiedler</pubmed_authors></additional><is_claimable>false</is_claimable><name>mRNA-seq of human cardiac fibrobasts (HCF) profibrotic stimulated with TGFb and treated with aloxistatin (E64d)</name><description>This study aimed to explore the therapeutic potential of the cysteine protease inhibitor aloxistatin (E64d) as a candidate to combat cardaic fibrotic progression. Human cardiac fibroblasts (HCFs) derived from diseased myocardium including ischemic and dilated cardiomyopathies (ICM, DCM) were treated for 48 h with 100 µM aloxistatin or DMSO control and pro-fibrotic stimulated with 5 ng/mL TGFβ1 or respective vehicle (veh) control (4 mM HCl containing 0.1% bovine serum albumin). HCF were harvested with QiAzol Lysis reagent (Qiagen) and RNA was isolated based on phenol-chloroform-extraction procedure.</description><dates><release>2026-07-06T00:00:00Z</release><modification>2026-07-06T15:05:10.4Z</modification><creation>2025-11-13T14:50:12.194Z</creation></dates><accession>E-MTAB-16034</accession><cross_references><ENA>ERP183922</ENA><EFO>EFO_0002944</EFO><EFO>EFO_0004170</EFO><EFO>EFO_0004917</EFO><EFO>EFO_0005518</EFO><EFO>EFO_0003816</EFO><EFO>EFO_0003738</EFO><EFO>EFO_0004184</EFO></cross_references></HashMap>